新华制药公告，第十一届董事会第八次会议于2025年8月26日召开，审议通过了公司2025年半年度报告及修订《公司章程》及相关议事规则的议案。会议应到董事9名，实际参会9名，监事会成员和非董事副总经理列席。修订议案需提交股东大会审议，通过后将废止监事、监事会及《监事会议事规则》，由董事会审核委员会行使相关职权。
Source Link新华制药公告，第十一届董事会第八次会议于2025年8月26日召开，审议通过了公司2025年半年度报告及修订《公司章程》及相关议事规则的议案。会议应到董事9名，实际参会9名，监事会成员和非董事副总经理列席。修订议案需提交股东大会审议，通过后将废止监事、监事会及《监事会议事规则》，由董事会审核委员会行使相关职权。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.